Pembrolizumab (for MSI-H/dMMR)
Treatment for Colon And Rectum Cancer
Typical Dosage: 200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Effectiveness
90%
Safety Score
45%
Clinical Trials
50
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
200 mg IV every 3 weeks or 400 mg IV every 6 weeks
Time to Effect
1-3 months
Treatment Duration
Until progression or up to 2 years
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$10,000
Side Effect Mgmt:$8,000
Total Annual:$168,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$112,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$336,000
Cost per Remission
$1,680,000
Comparison vs Chemotherapy (FOLFOX/FOLFIRI)
Cost Difference
+$123,000/year
More expensive
QALY Difference
+0.70 QALYs
Better outcomes
Dominance
No dominance
Pembrolizumab (for MSI-H/dMMR) Outcomes
for Colon And Rectum Cancer
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+50%
Remission Rate
+10%
Common Side Effects
Fatigue
+40%
Diarrhea/Colitis
+15%
Rash
+15%
Endocrinopathies
+7%
Pneumonitis
+4%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov